$Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis$

Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis

Background & AIMS Basiliximab is a chimeric monoclonal antibody that binds CD25 and thereby inhibits interleukin (IL)-2–mediated proliferation of lymphocytes. IL-2 might contribute to the resistance of T cells to corticosteroids. We investigated the efficacy and safety of basiliximab as a cortic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2012-08, Vol.143 (2), p.356-364.e1
Hauptverfasser:	Sands, Bruce E, Sandborn, William J, Creed, Tom J, Dayan, Colin M, Dhanda, Ashwin D, Van Assche, Gert A, Greguš, Miloš, Sood, Ajit, Choudhuri, Gourdas, Stempien, Mary Jean, Levitt, Daniel, Probert, Christopher S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Basiliximab Colitis, Ulcerative - drug therapy Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Gastroenterology and Hepatology Glucocorticoids - therapeutic use Humans IBD Immune Response Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use Induction Chemotherapy Male Middle Aged Prednisone - therapeutic use Randomized Clinical Trial Recombinant Fusion Proteins - pharmacokinetics Recombinant Fusion Proteins - therapeutic use Severity of Illness Index Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!